Optipharm: using the technology of different islets of Langerhans to seize the market of biological agents for diabetes treatment in China
- Categories:Enterprise dynamics
- Author:
- Origin:
- Time of issue:2020-03-19 16:35
- Views:
(Summary description)SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.Optipharm,aSouthKoreanlifesciencecompany,willusethetechnologyofdifferentisletsofLangerhanstoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.
Optipharm: using the technology of different islets of Langerhans to seize the market of biological agents for diabetes treatment in China
(Summary description)SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.Optipharm,aSouthKoreanlifesciencecompany,willusethetechnologyofdifferentisletsofLangerhanstoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.SouthKoreanlifesciencefirmoptipharmwillusexenoislettechnologytoenterthe27trillionwonChinesediabetestreatmentmarket,accordingtoSouthKoreanportalnaver.
- Categories:Enterprise dynamics
- Author:
- Origin:
- Time of issue:2020-03-19 16:35
- Views:
South Korean life science firm optipharm will use xeno islet technology to enter the 27 trillion won Chinese diabetes treatment market, according to South Korean portal naver. Optipharm, a South Korean life science company, will use the technology of different islets of Langerhans to enter the 27 trillion won Chinese diabetes treatment market, according to South Korean portal naaver. South Korean life science firm optipharm will use xeno islet technology to enter the 27 trillion won Chinese diabetes treatment market, according to South Korean portal naver. South Korean life science firm optipharm will use xeno islet technology to enter the 27 trillion won Chinese diabetes treatment market, according to South Korean portal naver. South Korean life science firm optipharm will use xeno islet technology to enter the 27 trillion won Chinese diabetes treatment market, according to South Korean portal naver. South Korean life science firm optipharm will use xeno islet technology to enter the 27 trillion won Chinese diabetes treatment market, according to South Korean portal naver. South Korean life science firm optipharm will use xeno islet technology to enter the 27 trillion won Chinese diabetes treatment market, according to South Korean portal naver. South Korean life science firm optipharm will use xeno islet technology to enter the 27 trillion won Chinese diabetes treatment market, according to South Korean portal naver.
Scan the QR code to read on your phone
